Condition: Bone Marrow Transplant Complications · Graft Versus Host Disease · Infection Viral · Sponsor: Hospital Israelita Albert Einstein
This study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a bone marrow graft from a matched unrelated donor in overall survival, progression free survival and cumulative incidence of acute and chronic GvHD. Thirty patients will receive cyclophosphamide while twenty patients will receive antihuman T-lymphocyte immune globulin (ATG).
This description comes directly from the study's public registry record.
Andreza A Feitosa Ribeiro · +5511992512523 · andreza.ribeiro@einstein.br
Always discuss trial participation with your own doctor first.
| Hospita Israelita Albert Eintein | São Paulo, São Paulo, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03818334